ZNHIT1 Knockout cell line (HT-29)

CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.

ZNHIT1 (zinc finger HIT-type containing 1) encodes a nuclear protein with histone-binding activity. It is involved in muscle cell differentiation and contributes to positive regulation of DNA damage responses mediated by p53-class signaling. Through its interactions with histones and participation in cellular response pathways, ZNHIT1 may contribute to coordination of chromatin-associated regulation, differentiation, and genome damage responses.

HT-29 is a human colorectal adenocarcinoma cell line established from a primary colon tumor of a 44-year-old female patient in 1964. The cells can undergo differentiation into mature goblet-like cells and produce mucin-secreting subclones, such as HT29-MTX, which exhibit characteristics of intestinal epithelial differentiation, including tight junction formation and mucus layer production. HT-29 is widely used as a model for studying colorectal cancer biology, intestinal epithelial differentiation, barrier function, and drug or nanoparticle transport.

Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.